T‐cell responses and therapies against SARS‐CoV‐2 infection
<p>Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, a novel coronavirus strain. Some studies suggest that COVID-19 could be an immune-related disease, and failure of effective immune responses in initial stages of viral infection could contribute to systemic inflammation and tissue...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , |
| منشور في: |
2023
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513566186405888 |
|---|---|
| author | Salman M. Toor (8854751) |
| author2 | Reem Saleh (3513056) Varun Sasidharan Nair (5396393) Rowaida Z. Taha (8854754) Eyad Elkord (5396390) |
| author2_role | author author author author |
| author_facet | Salman M. Toor (8854751) Reem Saleh (3513056) Varun Sasidharan Nair (5396393) Rowaida Z. Taha (8854754) Eyad Elkord (5396390) |
| author_role | author |
| dc.creator.none.fl_str_mv | Salman M. Toor (8854751) Reem Saleh (3513056) Varun Sasidharan Nair (5396393) Rowaida Z. Taha (8854754) Eyad Elkord (5396390) |
| dc.date.none.fl_str_mv | 2023-03-15T11:47:06Z |
| dc.identifier.none.fl_str_mv | 10.1111/imm.13262 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/T_cell_responses_and_therapies_against_SARS_CoV_2_infection/22258528 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Immunology Immunology Immunology and Allergy coronavirus COVID-19 immune responses SARS-CoV-2 T cells |
| dc.title.none.fl_str_mv | T‐cell responses and therapies against SARS‐CoV‐2 infection |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p>Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, a novel coronavirus strain. Some studies suggest that COVID-19 could be an immune-related disease, and failure of effective immune responses in initial stages of viral infection could contribute to systemic inflammation and tissue damage, leading to worse disease outcomes. T cells can act as a double-edge sword with both pro- and anti-roles in the progression of COVID-19. Thus, better understanding of their roles in immune responses to SARS-CoV-2 infection is crucial. T cells primarily react to the spike protein on the coronavirus to initiate antiviral immunity; however, T-cell responses can be suboptimal, impaired or excessive in severe COVID-19 patients. This review focuses on the multifaceted roles of T cells in COVID-19 pathogenesis and rationalizes their significance in eliciting appropriate antiviral immune responses in COVID-19 patients and unexposed individuals. In addition, we summarize the potential therapeutic approaches related to T cells to treat COVID-19 patients. These include adoptive T-cell therapies, vaccines activating T-cell responses, recombinant cytokines, Th1 activators and Th17 blockers, and potential utilization of immune checkpoint inhibitors alone or in combination with anti-inflammatory drugs to improve antiviral T-cell responses against SARS-CoV-2.</p> <h2>Other Information</h2> <p>Published in: Immunology<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br> See article on publisher's website: <a href="http://dx.doi.org/10.1111/imm.13262" target="_blank">http://dx.doi.org/10.1111/imm.13262</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_1af597d2c1f47acb4128864b567950e2 |
| identifier_str_mv | 10.1111/imm.13262 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/22258528 |
| publishDate | 2023 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | T‐cell responses and therapies against SARS‐CoV‐2 infectionSalman M. Toor (8854751)Reem Saleh (3513056)Varun Sasidharan Nair (5396393)Rowaida Z. Taha (8854754)Eyad Elkord (5396390)Biomedical and clinical sciencesImmunologyImmunologyImmunology and AllergycoronavirusCOVID-19immune responsesSARS-CoV-2T cells<p>Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, a novel coronavirus strain. Some studies suggest that COVID-19 could be an immune-related disease, and failure of effective immune responses in initial stages of viral infection could contribute to systemic inflammation and tissue damage, leading to worse disease outcomes. T cells can act as a double-edge sword with both pro- and anti-roles in the progression of COVID-19. Thus, better understanding of their roles in immune responses to SARS-CoV-2 infection is crucial. T cells primarily react to the spike protein on the coronavirus to initiate antiviral immunity; however, T-cell responses can be suboptimal, impaired or excessive in severe COVID-19 patients. This review focuses on the multifaceted roles of T cells in COVID-19 pathogenesis and rationalizes their significance in eliciting appropriate antiviral immune responses in COVID-19 patients and unexposed individuals. In addition, we summarize the potential therapeutic approaches related to T cells to treat COVID-19 patients. These include adoptive T-cell therapies, vaccines activating T-cell responses, recombinant cytokines, Th1 activators and Th17 blockers, and potential utilization of immune checkpoint inhibitors alone or in combination with anti-inflammatory drugs to improve antiviral T-cell responses against SARS-CoV-2.</p> <h2>Other Information</h2> <p>Published in: Immunology<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br> See article on publisher's website: <a href="http://dx.doi.org/10.1111/imm.13262" target="_blank">http://dx.doi.org/10.1111/imm.13262</a></p>2023-03-15T11:47:06ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1111/imm.13262https://figshare.com/articles/journal_contribution/T_cell_responses_and_therapies_against_SARS_CoV_2_infection/22258528CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/222585282023-03-15T11:47:06Z |
| spellingShingle | T‐cell responses and therapies against SARS‐CoV‐2 infection Salman M. Toor (8854751) Biomedical and clinical sciences Immunology Immunology Immunology and Allergy coronavirus COVID-19 immune responses SARS-CoV-2 T cells |
| status_str | publishedVersion |
| title | T‐cell responses and therapies against SARS‐CoV‐2 infection |
| title_full | T‐cell responses and therapies against SARS‐CoV‐2 infection |
| title_fullStr | T‐cell responses and therapies against SARS‐CoV‐2 infection |
| title_full_unstemmed | T‐cell responses and therapies against SARS‐CoV‐2 infection |
| title_short | T‐cell responses and therapies against SARS‐CoV‐2 infection |
| title_sort | T‐cell responses and therapies against SARS‐CoV‐2 infection |
| topic | Biomedical and clinical sciences Immunology Immunology Immunology and Allergy coronavirus COVID-19 immune responses SARS-CoV-2 T cells |